TP53 and myelodysplastic syndrome: The fact that poor prognosis in MDS/AMLs with TP53 mutation is mainly seen in patients with biallelic alterations [42]—where MDS/AML cells have no more functional p53–intuitively suggests that loss of wild-type p53 functions is the major oncogenic determinant, at least in late disease stages.